Almost Complete Response with a Single Administration 225Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary
Open accessAbstract
Neuroendocrine tumors (NETs) are being seen increasingly frequently, and the only known curative treatment method is surgical resection.Peptide receptor radionuclide therapy (PRRT) is a treatment option that the most contributes to progression-free survival and overall survival in metastatic cases.β-emittingradionuclides are traditionally used for PRRT.Nowadays, alpha particle-emitting radionuclides are being developed, with advantages in terms of very high energy and a short path length, which should theoretically show higher efficacy.In this case; in a patient with NET diagnosis who had multiple (>50) lesions in the abdomen, almost all the lesions disappeared with a single dose application.This paper aims to present a case in which we observed the efficacy of 225 Ac-DOTATATE treatment, which is an alpha treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a NET-CUP case report, the first case who received actinium-225 first line had almost complete response at a single dosage.
“First case who received actinium-225 first line with almost complete response at a single dosage”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2893-5 · Cited by 465 · see citing works
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215 · cited 1× · see citing works
“Although there are not enough studies on this topic in the literature, limited studies have shown that (225)Ac-DOTATATE is a promising treatment option, which adds a new dimension in patients especially who are refractory to (177)Lu-DOTATATE (5).”
BackgroundNavalkissoor, S., & Grossman, A. B. (2018) · Neuroendocrinology · doi:10.1159/000494760 · Cited by 99 · see citing works
Nayak, T. K., Norenberg, J. P., Anderson, T. L., Prossnitz, E. R., Stabin, M. G., & Atcher, R. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.11.006 · Cited by 73 · see citing works
Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor.
Ocak, M., Toklu, T., Demirci, E., Selçuk, N., & Kabasakal, L. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04725-x · Cited by 33 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
Rubira, L., Deshayes, E., Santoro, L., Kotzki, P. O., & Fersing, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041051 · Cited by 40 · see citing works
Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics
Munekane, M., Fuchigami, T., & Ogawa, K. (2024) · Analytical Sciences · doi:10.1007/s44211-024-00514-w · Cited by 25 · see citing works
Chandekar, K. R., & Bal, C. S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.06.008 · Cited by 12 · see citing works
Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy
Zuo, D., Wang, H. Z., Yu, B., Li, H., Gan, L., & Chen, W. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024206 · Cited by 9 · see citing works
Kuhlen, M., Karges, K., Kunstreich, M., Schmutz, M., Redlich, A., Claus, R., & Lapa, C. (2025) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2025.100318 · Cited by 2 · see citing works
Clinical perspective on targeted alpha therapy using 225Ac
Lim, I. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02117-5 · Cited by 2 · see citing works
- Authors
- Alan Selçuk, N., Demirci, E., Ocak, M., Toklu, T., Ergen, S., & Kabasakal, L.
- Affiliations
- Yeditepe University (TR)
- Istanbul University (TR)
- Istanbul University-Cerrahpaşa (TR)
- Corresponding author
- Kabasakal, Levent
- Venue
- Molecular Imaging and Radionuclide Therapy
- Publisher
- Galenos Yayinevi
- Published
- 2022-06-01
- Volume
- 31
- Issue
- 2
- Pages
- 139-141
- ISSN
- 2146-1414 (ISSN-L)
- 2147-1959
- PMC
- PMC9246299
- OpenAlex
- W4283660925
- Cited by
- 7
- References
- 5
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 1 · 2022: 1
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Molecular Imaging and Radionuclide Therapy (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Istanbul Technical University Academic Open Archive (Istanbul Technical University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- alpha-emitting radionuclides, peptide receptor radionuclide therapy, neuroendocrine tumors, metastatic neuroendocrine tumors, cancer of unknown primary, single-dose therapy, complete response, alpha therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
